PlainRecalls
FDA Drug Moderate Class II Ongoing

chlorproMAZINE Hydrochloride Tablets, USP, 10mg, 100-count bottle, RX only, Manufactured for: Glenmark Pharmaceuticals Inc., NJ; Product of India, NDC 68462-861-01

Reported: January 1, 2025 Initiated: December 11, 2024 #D-0159-2025

Product Description

chlorproMAZINE Hydrochloride Tablets, USP, 10mg, 100-count bottle, RX only, Manufactured for: Glenmark Pharmaceuticals Inc., NJ; Product of India, NDC 68462-861-01

Reason for Recall

CGMP Deviations: N-Nitroso-Desmethyl Chlorpromazine impurity (NNDCI) were found to be failing per current FDA recommended limit.

Details

Units Affected
3,888
Distribution
USA Nationwide
Location
Mahwah, NJ

Frequently Asked Questions

What product was recalled?
chlorproMAZINE Hydrochloride Tablets, USP, 10mg, 100-count bottle, RX only, Manufactured for: Glenmark Pharmaceuticals Inc., NJ; Product of India, NDC 68462-861-01. Recalled by Glenmark Pharmaceuticals Inc., USA. Units affected: 3,888.
Why was this product recalled?
CGMP Deviations: N-Nitroso-Desmethyl Chlorpromazine impurity (NNDCI) were found to be failing per current FDA recommended limit.
Which agency issued this recall?
This recall was issued by the FDA Drug on January 1, 2025. Severity: Moderate. Recall number: D-0159-2025.